Literature DB >> 26136991

Clinical features of post-infectious bronchiolitis obliterans in children undergoing long-term azithromycin treatment.

Xueyan Wang1, Changshan Liu1, Mengjuan Wang1, Y I Zhang1, Hewen Li2, Geli Liu3.   

Abstract

The aim of the present study was to outline any predisposing factors and clinical and radiological features of post-infectious bronchiolitis obliterans (PIBO) in pediatric patients, and to determine the effect of long-term azithromycin treatment on these factors. In total, 16 cases of children with PIBO were retrospectively reviewed. Adenovirus and Mycoplasma pneumoniae were the most common etiological agents (12/16) in the children with PIBO. The patients presented with persistent dyspnea, a chronic cough, sputum production and wheezing following the initial lung infection. Chest X-rays indicated pulmonary overinflation and patchy ground-glass opacity. In addition, high-resolution computed tomography (HRCT) scans revealed patchy ground-glass opacity, bronchiectasis, bronchial wall thickening and mosaic perfusion in all 16 cases. A unilateral hyperlucent lung was observed in two cases. All the patients underwent treatment with low-dose azithromycin and prednisone. Follow-up examinations of the 16 cases, varying in duration between 7 and 31 months, showed that the disease condition had improved in 10 cases. However, no significant improvements were identified from the HRCT scans or were observed in the patient condition in the additional six cases. The diagnosis of BO is primarily based on a typical clinical presentation and HRCT observations. Therefore, a typical clinical history and patchy ground-glass opacity features on HRCT scans are screening indices that predict BO development. Steroids are the cornerstone of BO treatment; however, long-term azithromycin treatment can improve the condition of the patients. In summary, PIBO is a disease with a high morbidity rate and should be treated by a multidisciplinary team. Patients should receive follow-up examination for an extended period. Patchy ground-glass opacity features on HRCT scans indicate that clinical suspicion of BO is necessary in children with persistent and severe wheezing.

Entities:  

Keywords:  azithromycin; child; post-infectious bronchiolitis obliterans; steroids

Year:  2015        PMID: 26136991      PMCID: PMC4473509          DOI: 10.3892/etm.2015.2418

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  29 in total

Review 1.  Computed tomography findings of postoperative complications in lung transplantation.

Authors:  Bruno Hochhegger; Klaus Loureiro Irion; Edson Marchiori; Rodrigo Bello; José Moreira; José Jesus Camargo
Journal:  J Bras Pneumol       Date:  2009-03       Impact factor: 2.624

Review 2.  Bronchiolitis obliterans syndrome: the Achilles' heel of lung transplantation.

Authors:  S Samuel Weigt; Ariss DerHovanessian; W Dean Wallace; Joseph P Lynch; John A Belperio
Journal:  Semin Respir Crit Care Med       Date:  2013-07-02       Impact factor: 3.119

Review 3.  Post-infectious bronchiolitis obliterans in children.

Authors:  Natália Silva Champs; Laura M L B F Lasmar; Paulo A M Camargos; Christophe Marguet; Gilberto Bueno Fischer; Helena Teresinha Mocelin
Journal:  J Pediatr (Rio J)       Date:  2011-05-05       Impact factor: 2.197

4.  Azithromycin reduces airway neutrophilia and interleukin-8 in patients with bronchiolitis obliterans syndrome.

Authors:  Geert M Verleden; Bart M Vanaudenaerde; Lieven J Dupont; Dirk E Van Raemdonck
Journal:  Am J Respir Crit Care Med       Date:  2006-06-01       Impact factor: 21.405

5.  Postinfectious bronchiolitis obliterans in children: clinical and pulmonary function findings.

Authors:  V Aguerre; C Castaños; H Gonzalez Pena; M Grenoville; P Murtagh
Journal:  Pediatr Pulmonol       Date:  2010-08-17

6.  Clinical prediction rule to diagnose post-infectious bronchiolitis obliterans in children.

Authors:  Alejandro J Colom; Alejandro M Teper
Journal:  Pediatr Pulmonol       Date:  2009-11

7.  Inhaled azithromycin therapy.

Authors:  Anthony J Hickey; Dongmei Lu; Elizabeth Dodds Ashley; Jason Stout
Journal:  J Aerosol Med       Date:  2006

8.  Lower respiratory infections by adenovirus in children. Clinical features and risk factors for bronchiolitis obliterans and mortality.

Authors:  Patricia Murtagh; Verónica Giubergia; Diana Viale; Gabriela Bauer; Hebe Gonzalez Pena
Journal:  Pediatr Pulmonol       Date:  2009-05

9.  Rapid acute onset of bronchiolitis obliterans syndrome in a lung transplant recipient after respiratory syncytial virus infection.

Authors:  D Hayes; H M Mansour; S Kirkby; A B Phillips
Journal:  Transpl Infect Dis       Date:  2012-06-01       Impact factor: 2.228

Review 10.  Respiratory viruses in lung transplant recipients: a critical review and pooled analysis of clinical studies.

Authors:  D-L Vu; P-O Bridevaux; J-D Aubert; P M Soccal; L Kaiser
Journal:  Am J Transplant       Date:  2011-05       Impact factor: 8.086

View more
  11 in total

1.  Combined pirfenidone, azithromycin and prednisolone in post-H1N1 ARDS pulmonary fibrosis.

Authors:  Avinandan Saha; Preyas J Vaidya; Vinod B Chavhan; Amolkumar Achlerkar; Jörg D Leuppi; Prashant N Chhajed
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2018-04-28       Impact factor: 0.670

2.  Clinical features of postinfectious bronchiolitis obliterans in children undergoing long-term nebulization treatment.

Authors:  Xiao-Mei Zhang; Ai-Zhen Lu; Hao-Wei Yang; Li-Ling Qian; Li-Bo Wang; Xiao-Bo Zhang
Journal:  World J Pediatr       Date:  2018-09-29       Impact factor: 2.764

3.  Effects of Inhaled Corticosteroids on Lung Function in Children With Post-infectious Bronchiolitis Obliterans in Remission.

Authors:  Haoqi Zheng; Xiuhua Yu; Yuquan Chen; Wenying Lin; Li Liu
Journal:  Front Pediatr       Date:  2022-05-10       Impact factor: 3.569

4.  Artificial Intelligence Algorithm-Based High-Resolution Computed Tomography Image in the Treatment of Children with Bronchiolitis Obliterans by Traditional Chinese Medicine Method of Resolving Phlegm and Removing Blood Stasis.

Authors:  Xiaoning Shi; Qing Zhou
Journal:  Contrast Media Mol Imaging       Date:  2022-05-27       Impact factor: 3.009

5.  Lung Clearance Index and Quantitative Computed Tomography of Post-Infectious Bronchiolitis Obliterans in Infants.

Authors:  Yoon Hee Kim; Hyun Joo Shin; In Suk Sol; Soo Yeon Kim; Jong Deok Kim; Haesung Yoon; Kyung Won Kim; Myung-Joon Kim; Mi-Jung Lee; Myung Hyun Sohn
Journal:  Sci Rep       Date:  2017-11-09       Impact factor: 4.379

6.  Presumptive Development of Fibrotic Lung Disease From Bordetella bronchiseptica and Post-infectious Bronchiolitis Obliterans in a Dog.

Authors:  Jared A Jaffey; Mark Harmon; Isabelle Masseau; Kurt J Williams; Carol Reinero
Journal:  Front Vet Sci       Date:  2019-10-10

Review 7.  Postinfectious Bronchiolitis Obliterans in Children: Diagnostic Workup and Therapeutic Options: A Workshop Report.

Authors:  Silvija-Pera Jerkic; Folke Brinkmann; Alistair Calder; Alicia Casey; Megan Dishop; Matthias Griese; Geoffrey Kurland; Mandy Niemitz; Sylvia Nyilas; Dirk Schramm; Ralf Schubert; Michael Tamm; Stefan Zielen; Martin Rosewich
Journal:  Can Respir J       Date:  2020-01-30       Impact factor: 2.409

8.  Follow-up on the therapeutic effects of a budesonide, azithromycin, montelukast, and acetylcysteine (BAMA) regimen in children with post-infectious bronchiolitis obliterans.

Authors:  Tingting Weng; Xixi Lin; Leying Wang; Jiamei Lv; Lin Dong
Journal:  J Thorac Dis       Date:  2021-08       Impact factor: 2.895

9.  Clinical Analysis and Risk Factors of Bronchiolitis Obliterans After Mycoplasma Pneumoniae Pneumonia.

Authors:  Hao-Qi Zheng; Yu-Cong Ma; Yu-Quan Chen; Yan-Yue Xu; Yan-Lin Pang; Li Liu
Journal:  Infect Drug Resist       Date:  2022-07-28       Impact factor: 4.177

10.  Serum YKL-40 levels may help distinguish exacerbation of post-infectious bronchiolitis obliterans from acute bronchiolitis in young children.

Authors:  Yoon Young Jang; Hye Jin Park; Hai Lee Chung
Journal:  Eur J Pediatr       Date:  2017-06-01       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.